|
Growing Midwestern Clinical Research Organization Selects OmniComm Systems to
Provide eClinical Solutions for Phase IV Studies
FT. LAUDERDALE, Fla., July 30, 2009 /PRNewswire-FirstCall/ -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM ) , a leader in integrated electronic data capture
(EDC) solutions for clinical trials announced today that a growing US Clinical Research
Organization (CRO) has selected OmniComm to provide eClinical solutions in connection
with two of the CRO’s Phase IV studies covering approximately 27 sites and more
than 700 subjects. Additional details were not disclosed. Phase IV studies take
place after a drug has been approved for marketing and are designed to provide broader
experience in evaluating the safety and effectiveness of the new medicine in larger
numbers of patients, subpopulations of patients, and to compare and/or combine it
with other available treatments.
"We are pleased to have been selected by this CRO to provide eClinical solutions
for these important Phase IV studies," said Cornelis F. Wit, OmniComm's President
and CEO. "We believe the broad scope of our integrated eClinical solutions, enhanced
by the recent acquisition of eResearch Technology’s data capture unit, positions
us well to offer a broad array of solutions, especially for CRO’s, pharmaceutical,
biotech and medical device companies seeking cost-effective tools to capture and
track outcomes of clinical trials conducted at multiple locations. We look forward
to expanding the range of services we provide for companies seeking to increase
efficiencies in their clinical activities."
Emerging Growth Equities, Ltd., President and CEO, Greg Berlacher stated, "We are
very excited about the opportunity to work with one of the fastest growing and innovative
companies in the EDC space today. We have worked with this management team in the
past and believe they have significant opportunities to gain market share in the
near future."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large scale institutions
to safely and efficiently capitalize on their clinical research investments. OmniComm
Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida and offices
in Bonn, Germany, Tula, Russia, California, Connecticut, Georgia, Illinois, New
Jersey, New York, North Carolina and Tennessee.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as the Company's
ability to obtain new contracts and accurately estimate net revenues due to uncertain
regulatory guidance, variability in size, scope and duration of projects, and internal
issues at the sponsoring client, integration of acquisitions, competitive factors,
technological development, and market demand. As a result, actual results may differ
materially from any financial outlooks stated herein. Further information on potential
factors that could affect the Company's financial results can be found in the Company's
Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.
The Company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
